{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:15:53Z","timestamp":1790162153999,"version":"4.1.0"},"reference-count":99,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2020,5,2]]},"DOI":"10.1080\/14656566.2020.1732350","type":"journal-article","created":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T13:05:04Z","timestamp":1583413504000},"page":"841-851","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":15,"title":["New and emerging pharmacotherapy for duchenne muscular dystrophy: a focus on synthetic therapeutics"],"prefix":"10.1080","volume":"21","author":[{"given":"Sharon M.","family":"Grages","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Regis University School of Pharmacy, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bell","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Regis University School of Pharmacy, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3727-952X","authenticated-orcid":false,"given":"Daniel J.","family":"Berlau","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Regis University School of Pharmacy, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,3,5]]},"reference":[{"key":"cit0001","unstructured":"Duchenne muscular dystrophy (DMD) | muscular dystrophy association. [Internet]. [cited 2019 Oct 27]. Available from: https:\/\/www.mda.org\/disease\/duchenne-muscular-dystrophy"},{"key":"cit0002","unstructured":"About duchenne muscular dystrophy | espeRare foundation. [Internet]. [cited 2019 Oct 27]. Available from: https:\/\/esperare.org\/en\/about-duchenne-muscular-dystrophy"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1177\/1756285610388693"},{"key":"cit0004","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1007\/s00894-013-1814-z","volume":"19","author":"Zhong J","year":"2019","journal-title":"Mol Med Rep"},{"key":"cit0005","unstructured":"Duchenne UK. Girls living with duchenne | duchenne UK. [Internet]. 2019 [cited 2020 Feb 4]. Available from: https:\/\/www.duchenneuk.org\/girls-living-with-duchenne"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.rehab.2013.06.002"},{"key":"cit0007","unstructured":"Patient education: overview of muscular dystrophies (beyond the basics) - uptodate. [Internet]. [cited 2020 Jan 16]. Available from: https:\/\/www.uptodate.com\/contents\/overview-of-muscular-dystrophies-beyond-the-basics#H8"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.3390\/jpm9010001"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002337"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2018.09.007"},{"key":"cit0011","doi-asserted-by":"crossref","unstructured":"Mcdonald CM, Henricson EK, Abresch RT, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. www.thelancet.com [Internet]. 2018 [cited 2019 Oct 22]. 391:451. Available from: http:\/\/dx.doi.org\/10.1016\/","DOI":"10.1016\/S0140-6736(17)32160-8"},{"key":"cit0012","unstructured":"Drugs@FDA: FDA approved drug products. [Internet]. [cited 2019 Oct 22]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=009766"},{"key":"cit0013","first-page":"38","volume":"27","author":"Rahman MM","year":"2001","journal-title":"Bangladesh Med Res Counc Bull"},{"key":"cit0014","unstructured":"Prednisone - Lexicomp. [Internet]. [cited 2019 Oct 22]. Available from: http:\/\/online.lexi.com"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003725.pub4"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003217"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1590\/0004-282x20190088"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1304-8"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-018-00687-z"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-016-0111-8"},{"key":"cit0021","unstructured":"Cushing\u2019s syndrome: learn about symptoms and treatment. [Internet]. [cited 2019 Oct 29]. Available from: https:\/\/www.medicinenet.com\/cushings_syndrome\/article.htm"},{"key":"cit0022","first-page":"783","author":"Enright PL","year":"2003","journal-title":"Respir Care"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26191"},{"key":"cit0024","unstructured":"Deflazacort - Lexicomp. [Internet]. [cited 2019 Oct 22]. Available from: http:\/\/online.lexi.com"},{"key":"cit0025","unstructured":"Emflaza medicare coverage and co-pay details - goodRx. [Internet]. [cited 2019 Oct 29]. Available from: https:\/\/www.goodrx.com\/emflaza\/medicare-coverage"},{"key":"cit0026","unstructured":"Request for prior authorization deflazacort (Emflaza). [cited 2019 Oct 28]; Available from: http:\/\/www.iowamedicaidpdl.com\/sites\/default\/files\/ghs-files\/prior-authorization-forms\/2017-08-23\/emflaza-pa-form-npi-oct-2017.pdf"},{"key":"cit0027","unstructured":"Your 2018 prescription drug list Oxford connecticut four-tier. [Internet]. 2018 [cited 2019 Oct 28]. Available from: https:\/\/www.oxhp.com\/druglist\/CTAdvantage3TierPDL.pdf"},{"key":"cit0028","unstructured":"Caremark. FEP 5 tier rx drug formulary (607) standard option. [Internet]. [cited 2019 Oct 28]. Available from: https:\/\/www.caremark.com\/portal\/asset\/z6500_drug_list.pdf"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.3233\/JND-180341"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.842"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008168"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-7-13"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1172\/JCI7866"},{"key":"cit0034","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.22024","volume":"67","author":"Malik V","year":"2010","journal-title":"Ann Neurol"},{"key":"cit0035","unstructured":"Aminoglycosides \u2013 UpToDate. [Internet]. [cited 2019 Oct 23]. Available from: https:\/\/www.uptodate.com\/contents\/aminoglycosides#H6"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2004.09.014"},{"key":"cit0037","first-page":"15","volume":"22","author":"Politano L","year":"2003","journal-title":"Acta Myol"},{"key":"cit0038","unstructured":"Prednisone \u2013 MICROMEDEX. [Internet]. [cited 2019 Nov 4]. Available from: https:\/\/www-micromedexsolutions-com"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.7b00269"},{"key":"cit0040","doi-asserted-by":"crossref","unstructured":"Hamada K, Omura N, Taguchi A, et al. New negamycin-based potent readthrough derivative effective against TGA-type nonsense mutations. 2019 [cited 2019 Oct 28]. Available from: https:\/\/pubs.acs.org\/sharingguidelines","DOI":"10.1021\/acsmedchemlett.9b00273"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31611-2"},{"key":"cit0042","unstructured":"PTC therapeutics receives formal dispute resolution request decision from the FDA\u2019s office of new drugs. [Internet]. [cited 2019 Oct 24]. Available from: https:\/\/www.drugs.com\/nda\/translarna_180220.html"},{"key":"cit0043","unstructured":"Translarna | European medicines agency. [Internet]. [cited 2019 Oct 23]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/translarna"},{"key":"cit0044","unstructured":"Long-term outcomes of ataluren in duchenne muscular dystrophy - full text view - clinicalTrials.gov. [Internet]. [cited 2019 Oct 29]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03179631?term=ataluren&cond=Duchenne+Muscular+Dystrophy&draw=3&rank=12"},{"key":"cit0045","unstructured":"Long-term outcomes of ataluren in duchenne muscular dystrophy - full text view - clinicaltrials.gov. [Internet]. [cited 2019 Oct 24]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03179631"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2019-0171"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1038\/nature05756"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000739"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1002\/humu.20918"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70195-4"},{"key":"cit0051","unstructured":"A clinical study to assess two doses of GSK2402968 in subjects with duchenne muscular dystrophy (DMD) - full text view - clinicaltrials.gov. [Internet]. [cited 2019 Oct 28]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01462292?term=NCT01462292&draw=2&rank=1"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.10.004"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.06.036"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2017.0682"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1002\/humu.22758"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0834-2"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60756-3"},{"key":"cit0058","doi-asserted-by":"crossref","unstructured":"Dystrophy M, Mendell JR, Rodino-klapac LR. Eteplirsen for the treatment of duchenne eteplirsen for the treatment of duchenne muscular dystrophy. 2013. 74(5); p. 637\u2013647.","DOI":"10.1002\/ana.23982"},{"key":"cit0059","unstructured":"FDA. Accelerated approval - NDA 206488. [Internet]. 2016 [cited 2019 Oct 28]. Available from: http:\/\/www.fda.gov\/ForIndustry\/DataStandards\/StructuredProductLabeling\/default.htm"},{"key":"cit0060","unstructured":"Eteplirsen - Lexicomp [Internet]. [cited 2019 Oct 24]. Available from: http:\/\/online.lexi.com"},{"key":"cit0061","unstructured":"Califf RM. Center for drug evaluation and research. 2016 [cited 2019 Oct 28]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/206488_summaryreview_Redacted.pdf"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.16437"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24555"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.07.014"},{"key":"cit0065","unstructured":"Study of SRP-4045 and SRP-4053 in DMD patients - full text view - clinicalTrials.gov. [Internet]. [cited 2019 Oct 29]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02500381"},{"key":"cit0066","unstructured":"An extension study to evaluate casimersen or golodirsen in patients with duchenne muscular dystrophy - full text view - clinicaltrials.gov. [Internet]. [cited 2019 Oct 29]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03532542"},{"key":"cit0067","unstructured":"FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation | FDA [Internet]. [cited 2020 Feb 7]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-first-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation"},{"key":"cit0068","volume":"90","author":"Muntoni F","year":"2018","journal-title":"Neurology"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.642"},{"key":"cit0070","unstructured":"P\u00e9ladeau C, Adam NJ, Jasmin BJ. Celecoxib treatment improves muscle function in mdx mice and increases utrophin A expression. [cited 2019 Oct 8]. Available from: www.fasebj.org"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddv444"},{"key":"cit0072","unstructured":"PoC study to assess activity and safety of SMT C1100 (Ezutromid) in boys with DMD - full text view - clinicaltrials.gov. [Internet]. [cited 2019 Oct 29]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02858362?term=PhaseOut+DMD&rank=1"},{"key":"cit0073","unstructured":"Gene transfer clinical trial to deliver rAAVrh74.MCK.GALGT2 for duchenne muscular dystrophy - full text view - clinicaltrials.gov. [Internet]. [cited 2019 Oct 29]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03333590"},{"key":"cit0074","first-page":"294(4):H1700\u20137","author":"Nakamura K","year":"2008","journal-title":"Am J Physiol - Hear Circ Physiol"},{"key":"cit0075","unstructured":"Rimeporide (EMD 87580) - muscular dystrophy news [Internet]. [cited 2019 Nov 4]. Available from: https:\/\/musculardystrophynews.com\/rimeporide-emd-87580\/"},{"key":"cit0076","unstructured":"Rimeporide in patients with duchenne muscular dystrophy - full text view - clinicaltrials.gov [Internet]. [cited 2019 Nov 4]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02710591?term=rimeporide&rank=1"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2018.09.017"},{"key":"cit0078","unstructured":"NS pharma announces NDA accepted for filing by the FDA for antisense oligonucleotide viltolarsen - parent project muscular dystrophy [Internet]. [cited 2020 Feb 10]. Available from: https:\/\/www.parentprojectmd.org\/ns-pharma-announces-nda-accepted-for-filing-by-the-fda-for-antisense-oligonucleotide-viltolarsen\/"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkm478"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2010.02.012"},{"key":"cit0081","unstructured":"Parent project muscular dystrophy annual conference [Internet]. 2018 [cited 2019 Oct 29]. Available from: https:\/\/www.parentprojectmd.org\/get-involved\/attend-events\/annual-conference\/2018-presentations\/"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.06.442"},{"key":"cit0083","unstructured":"Safety and tolerability of WVE-210201 in patients with duchenne muscular dystrophy - full text view - clinicalTrials.gov [Internet]. [cited 2019 Oct 29]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03508947"},{"key":"cit0084","unstructured":"Efficacy and safety study of WVE-210201 (Suvodirsen) with open-label extension in ambulatory patients with duchenne muscular dystrophy - full text view - clinicaltrials.gov [Internet]. [cited 2019 Oct 29]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03907072?term=WVE-210201&rank=1"},{"key":"cit0085","unstructured":"Wave life sciences announces discontinuation of suvodirsen development for duchenne muscular dystrophy nasdaq: WVE[Internet]. [cited 2020 Feb 10]. Available from: http:\/\/www.globenewswire.com\/news-release\/2019\/12\/16\/1960830\/0\/en\/Wave-Life-Sciences-Announces-Discontinuation-of-Suvodirsen-Development-for-Duchenne-Muscular-Dystrophy.html"},{"key":"cit0086","unstructured":"What is CRISPR, and how does it work? [Internet]. [cited 2019 Oct 29]. Available from: https:\/\/curiosity.com\/topics\/what-is-crispr-and-how-does-it-work-curiosity\/"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.07.040"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3628"},{"key":"cit0089","unstructured":"Systemic gene delivery clinical trial for duchenne muscular dystrophy - full text view - clinicaltrials.gov [Internet]. [cited 2019 Oct 29]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03375164"},{"key":"cit0090","unstructured":"Microdystrophin gene transfer study in adolescents and children with DMD - full text view - clinicaltrials.gov [Internet]. [cited 2019 Oct 29]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03368742"},{"key":"cit0091","unstructured":"A study to evaluate the safety and tolerability of PF-06939926 Gene therapy in duchenne muscular dystrophy - full text view - clinicaltrials.gov [Internet]. [cited 2019 Oct 29]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03362502"},{"key":"cit0092","unstructured":"Sarepta reports positive preliminary findings in DMD gene therapy trial - muscular dystrophy association [Internet]. [cited 2019 Oct 29]. Available from: https:\/\/strongly.mda.org\/sarepta-reports-positive-preliminary-findings-in-dmd-gene-therapy-trial\/"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.3390\/medicina47090068"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.3727\/096368913X672136"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00566"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24085"},{"key":"cit0097","unstructured":"Committee P and CNSDA. Eteplirsen briefing document [Internet]. 2016 [cited 2019 Nov 7]. Available from: https:\/\/www.fda.gov\/media\/97306\/download"},{"key":"cit0098","unstructured":"Mutation-specific therapies - parent project muscular dystrophy [Internet]. [cited 2019 Nov 4]. Available from: https:\/\/www.parentprojectmd.org\/about-duchenne\/what-is-duchenne\/types-of-mutations\/mutation-specific-therapies\/"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2019-0086"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2020.1732350","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T17:14:52Z","timestamp":1722532492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2020.1732350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,5]]},"references-count":99,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,5,2]]}},"alternative-id":["10.1080\/14656566.2020.1732350"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2020.1732350","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-11-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}